7.0 REFERENCES


Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI), Therapeutic Class Review (TCR), March 4, 2013


Brahmankar DM and Jaiswal SB. Biopharmaceutics and Pharmacokinetics A Treatise. 1st Edn., Vallabh Prakashan, New Delhi, 1999, 225


Brazilian health surveillance agency; General considerations for bioavailability and bioequivalence studies.


C. Lindsay DeVane, Metabolism and Pharmacokinetics of Selective Serotonin Reuptake Inhibitors. Cellular and Molecular Neurobiology, Vol. 19, No. 4, 1999.


Dubovsky SL. Severe nortriptyline intoxication due to change from a generic to a trade preparation. J Nerv Ment Dis. 1987; 175:115-117


International statistical classification of disease and health related problem (ICD-10): 10th revision; volume 02; 2010. WHO.


Malaysian guidelines for the conduct of bioavailability and bioequivalence studies; ministry of health, Malaysia; Ministry of Health Kuala Lumpur, September 2000


National Institute for Health and Clinical Excellence (NICE), clinical guideline Depression: the treatment and management of depression in adults, October 2009


SSRIs - Selective Serotonin Reuptake Inhibitors, emedexpert.com; updated in 2011 May
Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10(9):732-47


